Bone Biologics Corporation (BBLG) NASDAQ

2.10

-0.01(-0.47%)

Updated at September 18 11:05AM

Currency In USD

Bone Biologics Corporation

Address

2 Burlington Woods Drive

Burlington, MA 01803

United States of America

Phone

781 552 4452

Sector

Healthcare

Industry

Medical - Devices

Employees

2

First IPO Date

October 13, 2021

Key Executives

NameTitlePayYear Born
Mr. Jeffrey FrelickChief Executive Officer & President354,1091966
Ms. Deina H. Walsh CPAChief Financial Officer227,0541964

Description

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.